Christian Espinosa is the Founding CEO of Blue Goat Cyber, where he guides MedTech innovators through the complexities of FDA cybersecurity submissions. A US Air Force veteran with over 30 years of experience in offensive security, Christian transitioned his focus exclusively to medical devices after his own life was saved by one in 2022. He has helped clear over 250 devices with a 100% FDA success rate, ensuring that life-saving technology remains secure and trustworthy for the patients who need it most.
Company: Blue Goat Cyber
We are thrilled to have you join us today, welcome to ValiantCEO Magazine’s exclusive interview! Let’s start off with a little introduction. Tell our readers a bit about yourself and your company
Christian Espinosa: I’m Christian Espinosa, founder and CEO of Blue Goat Cyber, a cybersecurity firm that works exclusively with medical device manufacturers. We help companies get connected medical devices through FDA cybersecurity review, building the threat models, software bills of materials, and penetration test reports the FDA requires before it will clear a 510(k), De Novo, or PMA submission. My background is 30 years in cybersecurity across defense, critical infrastructure, and now MedTech, plus a stint founding and selling a previous company called Alpine Security in 2020.
What pulled me deeper into this specific niche was personal. In 2022 I had six blood clots, and the device that caught it in time was a portable Doppler ultrasound, a piece of connected medical technology that worked because it was secure. That experience turned a professional interest into something closer to a mission, and it’s part of why our team treats FDA cybersecurity submissions as patient safety work, not paperwork.
What was the defining moment or challenge that prompted you to pivot your business model, and how did you recognize it was time for a change?
Christian Espinosa: The real pivot in my career wasn’t a single crisis, it was a pattern I saw across years of running Alpine Security as a general cybersecurity firm. We’d take on penetration testing work across every industry, defense contractors, financial firms, whoever needed it, and the work was fine but it was also interchangeable with what a hundred other firms offered. Then in 2022 I had a serious health scare, six blood clots, and the device that caught it in time was a portable Doppler ultrasound. Lying in that situation, I understood in a very direct way that medical device security wasn’t just another vertical, it was a category where the stakes were literally life and death in a way general IT security never was.
That’s what told me it was time to stop being a generalist. I’d already sold Alpine Security in 2020 and spent time at Cerberus Sentinel, so I had the freedom to start something new, and I built Blue Goat Cyber to only serve medical device manufacturers. No general IT security work at all, just the narrow, deep problem of getting connected medical devices through FDA cybersecurity review.
Can you walk us through the most significant change you made to your business model and the immediate impact it had on your company’s trajectory?
Christian Espinosa: The significant change was going all-in on FDA submission work as the core product, rather than treating penetration testing as a standalone service. Instead of just delivering a generic pen test report and moving on, we restructured everything around what an FDA reviewer actually needs to clear a 510(k), De Novo, or PMA: the threat models traced to ISO 14971 patient safety hazards, the software bills of materials, the eSTAR-ready documentation, all built to work together as one submission package. We also built out a dedicated deficiency response service, since we kept encountering manufacturers who’d already submitted and gotten an FDA cybersecurity deficiency letter with no clear path forward.
The impact showed up fast in a metric that matters more than revenue to us, our clearance record. We’ve now done over 250 FDA submissions with zero cybersecurity rejections, and that number only makes sense because we stopped spreading ourselves across industries and started building deep, repeatable expertise in one regulatory pathway. Turnaround time also dropped, we’re typically at 2 to 4 weeks to get a client submission-ready, because we weren’t relearning a new industry’s compliance landscape with every client.
How did you convince your team, investors, or stakeholders to embrace such a dramatic shift, especially if it involved risk or uncertainty?
Christian Espinosa: Honestly, the health scare did most of the convincing for me internally, but for the team and early hires, the case was more practical than emotional. I showed them the math: a generalist cybersecurity firm competes on price against dozens of similar shops, but a firm that only does MedTech FDA submissions competes on almost nothing, because so few firms have the depth to do it well. I framed the risk not as “we’re narrowing our market” but as “we’re the only options left standing in a room that most competitors won’t even walk into.”
The other piece was proof through action rather than persuasion through argument. I didn’t ask anyone to trust a pitch deck, I took on the first handful of MedTech clients myself and let the results, faster clearances, cleaner deficiency resolutions, speak for the decision. Once the team saw manufacturers referring us to other manufacturers because we actually understood the regulatory pathway, the uncertainty mostly resolved itself.
What was the biggest obstacle you faced during the pivot, and how did you overcome it to ensure the new model’s success?
Christian Espinosa: The biggest obstacle was convincing medical device manufacturers to trust a cybersecurity firm that hadn’t spent decades exclusively in MedTech, even though I personally had 30 years in cybersecurity across defense and critical infrastructure. Manufacturers are understandably cautious, an FDA submission failure costs them months and sometimes their spot in the review queue, so nobody wants to be the test case for a firm’s new specialty. Early on, I had prospects ask why they should trust us over a firm that had been doing MedTech exclusively since day one.
I overcame it by leaning hard into the parts of the story that actually transferred, my red team and penetration testing background from Alpine Security, and by being upfront that we were narrowing our focus specifically so we could go deeper than anyone doing this as a side practice. We also built our credibility case one submission at a time rather than through marketing, tracking every clearance and turning that into a visible record. Once we hit zero cybersecurity rejections across dozens of submissions, the trust problem mostly disappeared on its own.
Looking back, what’s one key lesson from your pivot experience that you’d share with other CEOs considering a major business model shift?
Christian Espinosa: Narrow before you scale. It sounds counterintuitive, but the moment we stopped trying to serve every industry that needed cybersecurity and picked one narrow, high-stakes niche, everything else got easier: our messaging, our hiring, our client trust, even our own internal expertise. Generalist businesses feel safer because they have more potential customers, but in practice they compete on price and get stretched thin, while a narrow focus lets you become genuinely excellent at one specific, hard problem.
The other thing I’d tell them is that your pivot doesn’t need a perfect business case to start, it needs a real reason you believe in. Mine came from a health scare that made the stakes personal, but whatever the source, that conviction is what carries you through the early months when the new model hasn’t proven itself yet and the old model would have been the safer choice on paper.


